224 related articles for article (PubMed ID: 6600662)
21. Effect of probenecid on cerebrospinal fluid methotrexate kinetics.
Howell SB; Olshen RA; Rice JA
Clin Pharmacol Ther; 1979 Nov; 26(5):641-6. PubMed ID: 498706
[TBL] [Abstract][Full Text] [Related]
22. Active transport of methotrexate from cerebrospinal fluid in humans.
Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
24. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
25. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
26. [New aspects of the determination of blood methotrexate levels in leukemic children].
Schuler D; Borsi J; Koós R; Révész T; Kardos G; Somló P
Monatsschr Kinderheilkd; 1986 Oct; 134(10):765-8. PubMed ID: 3467178
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.
Rosen G; Ghavimi F; Nirenberg A; Mosende C; Mehta BM
Cancer Treat Rep; 1977 Jul; 61(4):681-90. PubMed ID: 301781
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
[TBL] [Abstract][Full Text] [Related]
29. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
30. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
32. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children.
Borsi JD; Moe PJ
Cancer; 1987 Dec; 60(12):3020-4. PubMed ID: 3479231
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate-vindesine association in leukemia: pharmacokinetic study.
Tubiana N; Lena N; Barbet J; Imbert AM; Lejeune C; Maraninchi D; Sainty D; Sebahoun G; Gastaut JA; Cano JP
Med Oncol Tumor Pharmacother; 1985; 2(2):99-102. PubMed ID: 3864001
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.
Evans WE; Abromowitch M; Crom WR; Relling MV; Bowman WP; Pui CH; Ochs J; Dodge R
NCI Monogr; 1987; (5):81-5. PubMed ID: 3481040
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.
Evans WE; Crom WR; Abromowitch M; Dodge R; Look AT; Bowman WP; George SL; Pui CH
N Engl J Med; 1986 Feb; 314(8):471-7. PubMed ID: 3456079
[TBL] [Abstract][Full Text] [Related]
36. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
Howell SB; Chu BB; Wung WE; Metha BM; Mendelsohn J
J Clin Invest; 1981 Apr; 67(4):1161-70. PubMed ID: 6970753
[TBL] [Abstract][Full Text] [Related]
37. Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse.
Morse M; Savitch J; Balis F; Miser J; Feusner J; Reaman G; Poplack D; Bleyer A
J Clin Oncol; 1985 Jan; 3(1):19-24. PubMed ID: 3855310
[TBL] [Abstract][Full Text] [Related]
38. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
39. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis.
Mehta BM; Glass JP; Shapiro WR
Cancer Res; 1983 Jan; 43(1):435-8. PubMed ID: 6600162
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia.
Najjar TA; al Fawaz IM
Chemotherapy; 1993; 39(4):242-7. PubMed ID: 8325125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]